Several brokerages have updated their recommendations and price targets on shares of Indivior PLC (LON: INDV) in the last few weeks:

  • 9/15/2017 – Indivior PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 470 ($6.07) price target on the stock.
  • 9/15/2017 – Indivior PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a GBX 400 ($5.17) price target on the stock.
  • 9/8/2017 – Indivior PLC had its price target lowered by analysts at Jefferies Group LLC from GBX 540 ($6.97) to GBX 358 ($4.62). They now have a “buy” rating on the stock.
  • 9/5/2017 – Indivior PLC had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 280 ($3.62) price target on the stock.
  • 9/1/2017 – Indivior PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 470 ($6.07) price target on the stock.
  • 8/11/2017 – Indivior PLC had its price target raised by analysts at Jefferies Group LLC from GBX 490 ($6.33) to GBX 540 ($6.97). They now have a “buy” rating on the stock.
  • 8/3/2017 – Indivior PLC had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a GBX 470 ($6.07) price target on the stock.
  • 7/28/2017 – Indivior PLC was upgraded by analysts at Royal Bank Of Canada to an “outperform” rating. They now have a GBX 470 ($6.07) price target on the stock, up previously from GBX 390 ($5.04).
  • 7/27/2017 – Indivior PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 490 ($6.33) price target on the stock.

Indivior PLC (LON:INDV) traded up 1.56% during mid-day trading on Friday, hitting GBX 300.10. 2,820,374 shares of the stock were exchanged. Indivior PLC has a 12-month low of GBX 246.50 and a 12-month high of GBX 421.50. The company has a 50 day moving average of GBX 370.68 and a 200 day moving average of GBX 336.58. The firm’s market cap is GBX 2.16 billion.

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.